Search
Linaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist. Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activato...
Baloxavir marboxil
go.drugbank.com/drugs/DB13997ApprovedInvestigational[L4779] It was also approved by the European Commission on January 7, 2021.[L45241]
Tabirafusp tedromer
go.drugbank.com/drugs/DB19340InvestigationalTabirafusp tedromer is under investigation in clinical trial NCT06556368 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants
Synonyms: 3,5,8-Trioxa-4-phosphaundec-10-en-1-aminium,4-hydroxy-N,N,N,10-tetramethyl-9-oxo-, inner salt, 4-oxide, homopolymer,9-arm star compd. with 1,1'-[2-[11,11-bis[15-bromo-11,11-bis[(2-bromo-2-methyl-1-oxopropoxyPF-04937319
go.drugbank.com/drugs/DB15009InvestigationalPF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
(+)-Mefloquine
go.drugbank.com/drugs/DB05636Investigationalcompare the efficacy of (+) Mefloquine vs. racemic [Mefloquine]. … (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to
Briakinumab
go.drugbank.com/drugs/DB05459InvestigationalAs of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
Budesonide
go.drugbank.com/drugs/DB01222ApprovedInvestigationalBudesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. Budesonide was granted FDA approval o...
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601]
Ociperlimab
go.drugbank.com/drugs/DB18947InvestigationalOciperlimab is under investigation in clinical trial NCT04866017 (A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (Ccrt) in Patients With Stage
Elzasonan
go.drugbank.com/drugs/DB18969InvestigationalElzasonan is under investigation in clinical trial NCT00275197 (A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive